[ET Net News Agency, 12 October 2018] Sino Biopharmaceutical (01177) said that
Bortezomib for Injection, an anticancer drug developed by Nanjing Chia Tai Tianqing
Pharmaceutical, a subsidiary of Sino Biopharm, has obtained approval for drug registration
by the National Medical Products Administration of the People's Republic of China.
It said Bortezomib is a new anticancer drug in targeted therapy, being mainly used for
treating multiple myeloma and mantle cell lymphoma. The approval obtained for the product
reflects that the group has further made solid progress in the field of blood cancer
treatment. It is expected that the product will be launched in the near future and more
patients in China will benefit from it. (KL)